TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Japan Airlines Signs 10-Year Boeing 787 Maintenance Deal With GE Aerospace 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Mistral AI Acquires Emmi AI to Expand Industrial AI Solutions in Europe 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
NEW YORK, Sept. 16, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Keryx Biopharmaceuticals, Inc. securities (NASDAQ:KERX) from February 25, 2016 through August 1, 2016, both dates inclusive (the “Class Period”) of the important October 3, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Keryx Biopharmaceuticals investors under the federal securities laws.
To join the Keryx Biopharmaceuticals class action, go to the firm’s website at http://rosenlegal.com/cases-927.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Keryx Biopharmaceuticals was experiencing production-related difficulties in converting API to finished drug product; (2) the issue was resulting in decreased production yields of finished drug product; and (3) as a result, defendants’ statements about Keryx Biopharmaceuticals’ business and operations were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-927.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
